Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

scientific article (publication date: 20 July 2004)

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/01.CIR.0000135467.43430.16
P3181OpenCitations bibliographic resource ID2589155
P698PubMed publication ID15238462

P50authorByung-Hee OhQ41652919
Kyung Woo ParkQ89316500
Young-Bae ParkQ116485843
Seock-Won YounQ117234749
Myoung-Mook LeeQ117234751
P2093author name stringSung-Hwan Kim
Han-Mo Yang
Hyo-Soo Kim
Kenneth Walsh
Hyun-Jeong You
Soo-In Jeon
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)301-308
P577publication date2004-07-06
P1433published inCirculationQ578091
P1476titleCelecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling
P478volume110

Reverse relations

cites work (P2860)
Q37408405Activation of Protein Kinase G (PKG) Reduces Neointimal Hyperplasia, Inhibits Platelet Aggregation, and Facilitates Re-endothelialization
Q36025935Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.
Q36342136Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling
Q28258964Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts
Q42059971COX-2 mediates PM2.5-induced apoptosis and inflammation in vascular endothelial cells
Q35607129Cardiovascular biology of microsomal prostaglandin E synthase-1.
Q36439704Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Q42701083Cardiovascular safety of celecoxib on top of dual antiplatelet therapy
Q47372560Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited
Q34021188Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
Q46548988Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Q46699523Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction
Q39819038Cellular membranes function as a storage compartment for celecoxib
Q34448421Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor.
Q45288661Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
Q28219713Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study
Q45854165Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial
Q53384415Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
Q35648213Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents
Q35693003HuR mediates the synergistic effects of angiotensin II and IL-1β on vascular COX-2 expression and cell migration
Q28200051Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation
Q39174244Insulin-like growth-factor-1-induced PKB signaling and Egr-1 expression is inhibited by curcumin in A-10 vascular smooth muscle cells
Q35103987Leukotriene-C4 synthase, a critical enzyme in the activation of store-independent Orai1/Orai3 channels, is required for neointimal hyperplasia
Q30557273Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury
Q37361545PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury
Q28478187Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion
Q34389006Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits
Q33744563Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of the phosphoinositide 3-kinase-Akt axis
Q36797387Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension
Q30475246Study of vascular injuries using endothelial denudation model and the therapeutic application of shock wave: a review.
Q45962157Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia.
Q53410809Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction.
Q104135011The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia
Q36419349The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production
Q38637342The protective effect of bee venom on fibrosis causing inflammatory diseases
Q42012970Utilization of thin film method for preparation of celecoxib loaded liposomes.

Search more.